Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like parsing medical jargon and regulatory code at once—especially when Femasys Inc. details FDA trial phases, device patents, and funding rounds in single documents. If you’ve opened the company’s 10-K only to search for pivotal FemBloc clinical data or revenue from FemaSeed, you’re not alone.
Stock Titan’s AI turns those dense reports into plain language summaries the moment they hit EDGAR. Instantly see which section of the Femasys quarterly earnings report 10-Q filing discusses cash runway, or receive real-time alerts when a director files Femasys insider trading Form 4 transactions. Our platform covers every form:
- 10-K and 10-Q filings—find R&D spend and market-launch timelines with one-click Femasys earnings report filing analysis
- 8-K updates—get Femasys 8-K material events explained, from FDA clearances to patent grants
- DEF 14A proxy—track Femasys proxy statement executive compensation and board governance tied to clinical milestones
- Form 4—monitor Femasys Form 4 insider transactions real-time to gauge executive confidence
Need answers fast? Ask natural questions like “How is FemVue revenue trending?”—our engine replies by linking the exact paragraph in the filing. Whether you’re understanding Femasys SEC documents with AI for due diligence or comparing insider buys via Femasys executive stock transactions Form 4, every disclosure is indexed, summarized, and searchable within minutes. Complex women’s-health innovations deserve clarity; we deliver it, so you can focus on investment decisions instead of page counts.
Femasys Inc. reported that it has secured U.S. FDA clearance for its next-generation FemVue diagnostic device. This clearance means the updated FemVue system has met the agency’s requirements for marketing in the United States. The company disclosed the news through a press release, which is included as an exhibit to this report.
The FemVue device is described as a diagnostic product, and the clearance relates specifically to its next-generation version. While no financial figures or commercial details are provided here, obtaining FDA clearance is often an important regulatory milestone for a medical device company, as it allows the cleared product version to be offered to healthcare providers in the U.S.
Femasys Inc. (FEMY) disclosed that its Chief Executive Officer and director filed a Form 4 reporting the purchase of derivative securities on 11/07/2025 for an aggregate amount of
The reporting person acquired Senior Secured Convertible Notes due 2035, initially convertible at
Femasys Inc. (FEMY) reported that it announced financial results for the quarter ended September 30, 2025 and provided a corporate update.
The company furnished a related press release as Exhibit 99.1. The information furnished, including Exhibit 99.1, is not deemed filed under the Exchange Act.
Femasys Inc. (FEMY) disclosed that a director reported a transaction on 11/07/2025 involving senior secured convertible notes and three warrant series. The reported securities were purchased for an aggregate amount of $25,000.
The notes are convertible at an initial price of $0.73 per share into up to 34,122 shares of common stock, with shares potentially increasing as interest accrues and subject to Nasdaq-related limitations. The Series A-1, Series B-1, and Series C-1 warrants each cover 34,122 shares at initial exercise prices of $0.81, $0.92, and $1.10 per share, respectively. All instruments list an expiration of 11/07/2035 and include customary adjustment provisions for events such as stock splits or dividends.
Femasys Inc. (FEMY) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/07/2025, the officer acquired Senior Secured Convertible Notes and three warrant series (A-1, B-1, C-1) for an aggregate purchase amount of $25,000.
The notes are initially convertible at $0.73 per share and are linked to up to 34,122 underlying shares based on the original stated amount, with conversion subject to specified limitations. Each of the Series A-1, B-1, and C-1 warrants covers 34,122 underlying shares, became exercisable on 11/07/2025, and expires on 11/07/2035, with initial exercise prices of $0.81, $0.92, and $1.10 per share, respectively. Conversion and exercise terms are adjustable per the instruments’ provisions.
Femasys Inc. filed a Form 8-K reporting a business update and furnished a press release titled “Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe.”
The disclosure indicates expanding commercial activity for FemBloc through a partner order in the European market. The press release is included as Exhibit 99.1 and is dated November 10, 2025.
Femasys Inc. announced a private placement of senior secured convertible notes and accompanying warrants for expected aggregate gross proceeds of $12 million, closing in two tranches on November 7 and November 26, 2025, subject to customary conditions.
The notes carry 8.50% annual interest paid in kind, mature in ten years, and are initially convertible at $0.73 per share. Warrants are split across series with exercise prices of $0.81, $0.92, and $1.10 per share, with certain series expiring earlier if specified commercial or regulatory milestones are publicly disclosed. The company plans to use net proceeds to repay senior convertible notes issued in November 2023 no later than their stated maturity, and for working capital and general corporate purposes.
The financing is secured by substantially all assets. A 19.99% issuance cap applies absent stockholder approval, which the company intends to seek. Registration rights require filing a resale registration for 100% of conversion and warrant shares within six months of the first closing. Insiders purchased approximately $100,000 on the same terms. The lead lender receives a board nomination right subject to ownership and time-based fall-away and agreed to a standstill, including a 30% beneficial ownership cap.
Femasys Inc. (FEMY) announced FDA approval to advance the final FemBloc trial phase and a financing of $12 million, with potential to reach $58 million. The company disclosed these developments via a press release furnished as an exhibit. FDA clearance to proceed in the trial process is a key step toward generating pivotal clinical data for FemBloc, while the financing provides added capital to support program execution.
The announcement pairs a regulatory milestone with near-term funding. The $12 million financing, and the stated potential to reach $58 million, signal additional resources that can help sustain clinical progress and operations as the FemBloc program advances.
Femasys Inc. updated its Nasdaq listing status. The company previously fell below Nasdaq’s $35.0 million Market Value of Listed Securities threshold, but now believes it satisfies an alternative standard. Based on pro forma data reflecting its underwritten offering and subsequent warrant exercises, Femasys estimates stockholders’ equity was approximately $5.2 million as of October 15, 2025, exceeding Nasdaq’s $2.5 million minimum for continued listing.
Nasdaq will continue to monitor compliance. If the next periodic report does not evidence the stockholders’ equity requirement, the company may be subject to delisting. The earlier financing included common stock, pre-funded warrants and warrants with gross proceeds of $8.0 million.
Femasys Inc. (FEMY) announced the planned retirement of Chief Operating Officer Daniel Currie, effective December 15, 2025. He will continue in his current role until his departure.
Carrie’s retirement follows more than 20 years with the company, having joined in March 2004, and is attributed to personal health considerations and a desire to focus on family. In connection with the transition, the company and Mr. Currie entered into a Separation and General Release Agreement on October 16, 2025, filed as Exhibit 10.1. Femasys expressed appreciation for his leadership and service.
FAQ
What is the current stock price of FEMASYS (FEMY)?
What is the market cap of FEMASYS (FEMY)?
